Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01721057 · ClinicalTrials.gov registry record · Phase 3
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 684
- Enrollment target
NCT01721057: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT01721057 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 684 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01721057, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 684 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily (QD) is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had inadequate response to or are intolerant to at least 1 conventional disease-modifying antirheumatic drug (cDMARD)(cDMARD-IR \[inadequate response\] participants) and who have not received a biologic disease-modifying antirheumatic drug (DMARD).
Primary Outcome
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). "ACR20 Responder" is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity using visual analog scale (VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI), pain due to arthritis, and high-sens
Interventions
- DRUG Placebo
- DRUG Baricitinib
- DRUG cDMARD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 684 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
What the finished NCT01721057 record still lists
NCT01721057 is an interventional study that assigns participants to a tested intervention. The registered 684 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01721057 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01721057 about?
NCT01721057 is a clinical study titled "A Study in Moderate to Severe Rheumatoid Arthritis Participants". The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily (QD) is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had inadequate response to or are intolerant to at least 1 conventional disease...
What is the current status of trial NCT01721057?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 684 participants. The study started on 2012-12. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01721057?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG), cDMARD (DRUG).
Who is sponsoring clinical trial NCT01721057?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01721057's enrollment target sits among peer trials
684 528th of 2000 higher than 1,472 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06795087 · 684 participants
Discharge Medication Use Post-Operatively in GU Cancer Patients
- NCT05099770 · 685 participants · Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- NCT05880199 · 685 participants
BSGM to Evaluate Patients With GI Symptoms
- NCT04333537 · 686 participants · Phase 2
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia